Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Payables (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Payables for 4 consecutive years, with $867062.0 as the latest value for Q4 2025.

  • Quarterly Payables fell 25.19% to $867062.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $867062.0 through Dec 2025, down 25.19% year-over-year, with the annual reading at $867062.0 for FY2025, 25.19% down from the prior year.
  • Payables for Q4 2025 was $867062.0 at bioAffinity Technologies, down from $1.1 million in the prior quarter.
  • The five-year high for Payables was $1.5 million in Q1 2025, with the low at $146537.0 in Q1 2023.
  • Average Payables over 4 years is $761162.6, with a median of $839807.5 recorded in 2023.
  • The sharpest move saw Payables skyrocketed 388.64% in 2024, then dropped 25.19% in 2025.
  • Over 4 years, Payables stood at $345042.0 in 2022, then surged by 75.28% to $604789.0 in 2023, then skyrocketed by 91.63% to $1.2 million in 2024, then decreased by 25.19% to $867062.0 in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $867062.0, $1.1 million, and $1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.